Ammonio Methacrylate Copolymer Type B
Medically reviewed by Drugs.com. Last updated on Jun 12, 2023.
Excipient (pharmacologically inactive substance)
What is it?
Ammonio methacrylate copolymers are excipients used in pharmaceutical manufacturing. Ammonio methacrylate copolymers are compounds derived from ethyl acrylate, methyl methacrylate and a low content of methacrylic acid ester with quaternary ammonium groups. They are solid substances in the form of a white powder with a faint amine-like odor. The ammonium groups are present as salts and make the polymers permeable. They are used in the manufacture of time-released products that are pH-independent in the pharmaceutical industry.
List of medications using Ammonio Methacrylate Copolymer Type B
- Acetazolamide Extended Release 500 mg
- Amphetamine and Dextroamphetamine Extended Release 5 mg
- Amphetamine and Dextroamphetamine Extended Release 20 mg
- Amphetamine and Dextroamphetamine Extended Release 30 mg
- Amphetamine and Dextroamphetamine Extended Release 10 mg
- Amphetamine and Dextroamphetamine Extended Release 15 mg
- Amphetamine and Dextroamphetamine Extended Release 25 mg
- Aptensio XR 40 mg
- Cartia XT 120 mg
- Dexmethylphenidate Hydrochloride Extended-Release 10 mg
- Dexmethylphenidate Hydrochloride Extended-Release 15 mg
- Dexmethylphenidate Hydrochloride Extended-Release 5 mg
- Dexmethylphenidate Hydrochloride Extended-Release 20 mg
- Diltiazem Hydrochloride Extended-Release 240 mg
- Diltiazem Hydrochloride Extended-Release 120 mg
- Diltiazem Hydrochloride Extended-Release 240 mg
- Diltiazem Hydrochloride Extended-Release 120 mg
- Diltiazem Hydrochloride Extended-Release 180 mg
- Diltiazem Hydrochloride Extended-Release 120 mg
- Diltiazem Hydrochloride Extended-Release 180 mg
References
- Evonik Industries. Eudragit RL PO. Accessed January 10, 2014. http://eudragit.evonik.com/product/eudragit/en/products-services/eudragit-products/sustained-release-formulations/rl-po/Pages/default.aspx
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
